Vaccitech (NASDAQ:VACC) Shares Down 2.9%

Shares of Vaccitech plc (NASDAQ:VACC) were down 2.9% during trading on Wednesday . The stock traded as low as $1.50 and last traded at $1.50. Approximately 10,490 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 244,643 shares. The stock had previously closed at $1.55.

Vaccitech Stock Down 2.9 %

The company’s fifty day moving average price is $1.87 and its two-hundred day moving average price is $2.49. The firm has a market cap of $57.82 million, a PE ratio of -1.05 and a beta of -0.40.

Institutional Trading of Vaccitech

A hedge fund recently bought a new stake in Vaccitech stock. M&G Plc acquired a new position in shares of Vaccitech plc (NASDAQ:VACC) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 5,197,349 shares of the company’s stock, valued at approximately $25,987,000. M&G Plc owned 13.48% of Vaccitech at the end of the most recent reporting period. Institutional investors and hedge funds own 26.13% of the company’s stock.

Vaccitech Company Profile

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.